1Jean Jacques Michels,Marnay Jacques,Michel Henry-Amar,et al.Prevalence and prognostic significance of tall cell variant of papillary thyroid carcinoma[J].Human Pathology,2007,38(2):212-219.
2Peter M.Sadow,Jennifer L.Hunt.Update on clinically important variants of papillary thyroid carcinoma[J].Diagnostic Histopathology,2011,17(3):106-113.
3Andrew J.Gaudena,Stanislaw J.Gaudenb.Multiple cerebral metastases as a primary presentation in papillary thyroid carcinoma[J].Journal of Clinical Neuroscience,2010,17(3):379-380.
4Shin E,Chung WY,Yang WI,et al.RET/PTC and CK19 expression in papillary thyroid carcinoma and its clinicopathologic correlation[J].J Korean Med Sci,2005,20(1):98-104.
5Sawangareetrakul P,Srisomsap C,Chokchaichamnankit D,et al.Galectin-3 expression in human papillary thyroid carcinoma[J].Cancer Genomics Proteomics,2008,5(2):117-22.
6Dongbin Ahna,June Sik Parka,Jin Ho Sohn,et al.BRAFV600E mutation does not serve as a prognostic factor in Korean patients with papillary thyroid carcinoma[J].Auris Nasus Larynx,2011,7(11):1016.
9Kimura ET, Nikiforova MN, Zhu ZW, et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma [J]. Cancer Res, 2003,63(7) : 1454 -1457.
10Salvatore G,Giannini R, Faviana P, et al. Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma [J]. J Clin Endocrinol Metab, 2004,89 (10) : 5157-5180.
